Multimodal recurrence risk prediction model for HR+/HER2- early breast cancer following adjuvant chemo-endocrine therapy: integrating pathology image and clinicalpathological features

Multimodal recurrence risk prediction model for HR+/HER2- early breast cancer following adjuvant chemo-endocrine therapy: integrating pathology image and clinicalpathological features

Abstract Background In HR+/HER2- early breast cancer (EBC) patients, approximately one-third of stage II and 50% of stage III patients experience recurrence, with poor outcomes after recurrence. Given that these patients commonly undergo adjuvant chemo-endocrine therapy (C-ET), accurately predicting...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaoyan Wu, Yiman Li, Jilong Chen, Jie Chen, Wenchuan Zhang, Xunxi Lu, Xiaorong Zhong, Min Zhu, Yuhao Yi, Hong Bu
Format: Article
Language:English
Published: BMC 2025-03-01
Series:Breast Cancer Research
Subjects:
HR+/HER2- early breast cancer
Recurrence risk
Adjuvant chemo-endocrine therapy
Deep learning pipelines
Pathology image
Online Access:https://doi.org/10.1186/s13058-025-01968-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items